glp-1 trial results today AstraZeneca's elecoglipron just posted some of the most closely watched Phase IIb data of the year and it landed at the right conference. from the VISTA and SOLSTICE trials, published simultaneously expected weight loss semaglutide results

The FDAs warning letter program serves an important function: it identifies and publicly documents violations, puts the industry on notice about enforcement priorities, and creates a public record that patients and providers can use to evaluate pharmacy compliance

Their hormonal systems have adapted to lower insulin environments

LASSS may be more easily accessible to the aforementioned internal disulfide bonds than GSSSG because LASSS (FW: 238.39) is about one-third the size of GSSSG (FW: 644.70)

It is not prescribed for weight loss

adult usage of weight-loss medications has more than doubled from 5.8% in early 2024 to 12.4% in 2Q/3Q 2025